MedXY News - CAR-T

$Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma$

Hematology-OncologyCAR-TGPRC5D

Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

By MedXY|Nov 17, 2025

In a phase 1 study of 18 heavily pretreated patients, the fully human VHH-based anti-GPRC5D CAR T-cell therapy RD118 achieved a 94.4% overall response rate, 72.2% CR/sCR, median PFS 18.2 months, and an acceptable safety profile with predomi

CAR-T

Latest news

Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis

EBMT Crosses One Million Transplants as Allogeneic HCT and CAR-T Reach New Highs in European Cellular Therapy

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity

Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients